Palabras clave
Cómo citar
Resumen
El objetivo del presente trabajo fue presentar una serie de casos de COVID-19 con manifestaciones atípicas de la enfermedad. Los casos fueron atendidos por un equipo interdisciplinario de personal de la salud de una clínica de cuarto nivel en Barranquilla, Colombia, y posteriormente los investigadores tomaron los datos de las historias clínicas. Se evaluaron tres casos: el primero tuvo evolución tórpida y coinfección con virus de la influenza H1N1 y los otros dos, manifestaciones gastrointestinales como debut de la enfermedad; todostuvieron desenlace satisfactorio.
La pandemia por SARS-CoV-2 cada día cobra más vidas, por lo que para identificar oportunamente a los infectados y tomar medidas tanto terapéuticas como de prevención y así evitar la propagación de la enfermedad y lograr su control, es necesario realizar reportes de caso en donde se evidencie la diversa variedad de presentaciones de COVID-19.
Citas
Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses - a statement of the Coronavirus Study Group. BioRxiv. 2020 [citado May 2020]. Dispomible en: https:// www.biorxiv.org/content/10.1101/2020.02.07.937862v1.full.
Organización Mundial de la Salud (OMS). Nuevo coronavirus- China. Ginebra: OMS; 2020.
World Health Organization (WHO). Coronavirus disease 2019 - Situation report 114. Geneve: WHO; 2020 [citado May 2020]. Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
Colombia. Instituto Nacional de Salud (INS). COVID-19 Colombia. Reporte 06-05-2020. Bogotá D.C.: INS; 2020.
Fung TS, Liu DX. Human Coronavirus: Host-Pathogen Interaction. Annu Rev Microbiol. 2019;73(1):529-57.
Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and coronaviruses. Viruses. 2019;11(1):41.
https://doi.org/10.3390/v11010041.
Arabi YM, Asiri AY, Assiri AM, Aziz-Jokhdar HA, Alothman A, Balkhy HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 2020;21(1):8. https://doi.org/10.1186/s13063-019-3846-x.
Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313-24. https://doi.org/10.4014/jmb.2003.03011.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;381(18):1708-20. https://doi.org/10.1056/NEJMoa2002032.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel CoronavirusInfected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. https://doi.org/10.1001/jama.2020.1585.
Joseph T, Moslehi MA. International pulmonologist’s consensus on COVID-19. 2020.
Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. https://doi.org/10.1001/jama.2020.2648.
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus(2019-nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441-7. https://doi.org/10.1002/jmv.25689.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199-207. https://doi.org/10.1056/NEJMoa2001316.
Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020;133(9):1015-24. https://doi.org/10.1097/CM9.0000000000000722.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirusin Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5.
Rothan HA, Byrareddy SN. The epidemeology and pathogensis of coronavirus (Covid-19) outbreak. J Autoimmun. 2020;109:02433. https://doi.org/10.1016/j.jaut.2020.102433.
Otto A. Unusual Presentations of COVID-19: “Our Ignorance Is Profound.” medscape. 2020;1-2.
Agarwal A, Chen A, Ravindran N, To C, Thuluvath PJ. Gastrointestinal and Liver Manifestations of COVID-19. J Clin Exp Hepatol. 2020;10(3):2637-5. https://doi.org/10.1016/j.jceh.2020.03.001.
Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID19. Kidney Int. 2020;97(5):829-38. https://doi.org/10.1016/j.kint.2020.03.005.
Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D. Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia. Am J Roentgenol. 2020;(1):1-6. https://doi.org/10.2214/AJR.20.22961.
Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020. https://doi.org/10.1001/jama.2020.4683.
Azekawa S, Namkoong H, Mitamura K, Kawaoka Y, Saito F. Co-infection with SARS-CoV-2 and influenza A virus. IDCases. 2020;20:e00775. https://doi.org/10.1016/j.idcr.2020.e00775.
Tang X, Du RH, Wang R, Cao TZ, Guan LL, Yang CQ, et al. Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1. Chest. 2020; S0012-3692(20)30558-4. https://doi.org/10.1016/j.chest.2020.03.032.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949. https://doi.org/10.1016/j.ijantimicag.2020.105949.
Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis. medRxiv. 2020;2842. https://doi.org/10.1101/2020.03.30.20048058.
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de Creative Commons Reconocimiento- NoComercial- SinObraDerivada 4.0 Internacional. que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.